Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9213879 | 0.96 | L3MBTL1 (0.39) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9213248 | 0.95 | KMT2A (0.40) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9218677 | 0.95 | L3MBTL1 (0.39) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9211389 | 0.95 | MEN1 (0.46) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9215732 | 0.94 | EGFR (0.38) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9209170 | 0.94 | MEN1 (0.46) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL6936582 | 0.94 | L3MBTL1 (0.49) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9221161 | 0.94 | L3MBTL1 (0.38) | MEN1KMT2AL3MBTL1PTPN1NPSR1 | |
| SCHEMBL9222024 | 0.93 | ESR1 (0.39) | MEN1KMT2AL3MBTL1PTPN1EGFR | |
| SCHEMBL9218854 | 0.93 | PTPN1 (0.40) | KMT2AL3MBTL1PTPN1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| EP-0512570-B1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-10-11 | — | — | EP | claimed |
| EP-0512570-A1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-11 | — | — | EP | claimed |
| JP-5140102-A | — | — | None | — | — | JP | disclosed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | PURDUE RESEARCH FOUNDATION (US) | 2025-03-25 | — | — | US | disclosed |
| EP-0943327-B1 | MEDICINAL COMPOSITION | ASTELLAS PHARMA INC (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6346537-B1 | ADMINISTERING A MACRO-TRI-HETEROCYCLIC COMPOUND AS ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0943327-A1 | MEDICINAL COMPOSITION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-22 | — | — | EP | disclosed |
| EP-0512570-B1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-10-11 | — | — | EP | disclosed |
| JP-H05140102-A | UREA DERIVATIVE AND ITS PRODUCTION | FUJISAWA PHARMACEUT CO LTD | 1993-06-08 | — | — | JP | disclosed |
| EP-0512570-A1 | Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | ACAT2, ACAT1, LCAT | MEN1 983/4885KMT2A 238/4885L3MBTL1 1228/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | MEN1 4241/4885KMT2A 866/4885L3MBTL1 2043/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | MEN1 1081/4885KMT2A 340/4885L3MBTL1 2288/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | MEN1 2495/4885KMT2A 779/4885L3MBTL1 1448/4885 |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | ACAT2, ACAT1, LCAT | MEN1 2495/4885KMT2A 779/4885L3MBTL1 1448/4885 |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | GLP1R, GPR119, FABP4 | MEN1 4718/4885KMT2A 1301/4885L3MBTL1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.